BioSight Ltd. is a biopharmaceutical company developing a pipeline
of pro-drug guided vectors that can target and release therapeutic
drugs directly into cancerous tumors, while significantly minimizing
the side effects associated with chemotherapy treatments.
BioSight is located in Karmiel - at the heart of the Galilee area - and is
a “made in Israel” company, with its entrepreneurs, team, intellectual
property, investors, shareholders and government financial support
all coming from Israel.
BioSight’s novel and proprietary drug targeting platform technology
S2DOT (Seek to Destroy Only Target) is applicable to a wide range of
cancer types and designed to:
• Target and release the drug selectively to
• Significantly minimize side effects arising from
• Increase efficacy using increased therapeutic doses.
The company’s intellectual property is a keystone in its corporate
strategy. BioSight has already filed three families of patents, while the
platform technology patent has already been granted.
The company’s lead compound, BST105, has already demonstrated
an exceptional safety profile in toxicological studies and proof of
concept in vitro and in vivo, and aims to begin human clinical trials.
BioSight’s future plans include creating new vectors to target a variety
of acute cancers, identifying new targets for drug discovery and
diagnostics and applying the technology to other areas, including
inflammatory and infectious diseases.
BioSight’s technology is developed with the aim of becoming a major
player in the multibillion-dollar cancer and drug delivery markets.
BioSight’s mission is to carry out the “drug revolution” which will change
the way medicine grapples with cancer.
Watch movie >>